Evidence map›Paper›PMID 40864768›Full record

ReviewCurrent issues in molecular biology2025

Oxidative-Inflammatory Crosstalk and Multi-Target Natural Agents: Decoding Diabetic Vascular Complications.

Jingwen Liu, Kexin Li, Zixin Yi, Saqirile, Changshan Wang, Rui Yang

Abstract readReview
In one paragraph

Review in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. International journal of molecular sciences · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingwen LiuSchool of Life Science, Inner Mongolia University, Hohhot 010020, China.
Kexin LiSchool of Life Science, Inner Mongolia University, Hohhot 010020, China.ORCID 0009-0001-7193-0534
Zixin YiSchool of Life Science, Inner Mongolia University, Hohhot 010020, China.
SaqirileSchool of Life Science, Inner Mongolia University, Hohhot 010020, China.
Changshan WangSchool of Life Science, Inner Mongolia University, Hohhot 010020, China.ORCID 0000-0001-6875-3138
Rui YangDepartment of Pharmacology, School of Basic Medicine, Inner Mongolia Medical University, Hohhot 010110, China.

Funding

National Natural Science Foundation of China Nos. 32460149National Natural Science Foundation of China Nos. 81660024Natural Science Foundation of Inner Mongolia Autonomous Region No. 2020MS08096Natural Science Foundation of Inner Mongolia Autonomous Region No. 2024MS08036
6 · The paper itself

Abstract

Diabetes mellitus (DM) is one of the leading causes of death and disability worldwide and its prevalence continues to rise. Chronic hyperglycemia exposes patients to severe complications. Among these, diabetic vascular lesions are the most destructive. Their primary driver is the synergistic interaction between hyperglycemia-induced oxidative stress and chronic inflammation. This review systematically elucidates how multiple pathological pathways-namely, metabolic dysregulation, mitochondrial dysfunction, endoplasmic reticulum stress, and epigenetic reprogramming-cooperate to drive oxidative stress and inflammatory cascades. Confronting this complex pathological network, natural products, unlike conventional single-target synthetic drugs, exert multi-target synergistic effects, simultaneously modulating several key pathogenic networks. This enables the restoration of redox homeostasis and the suppression of inflammatory responses, thereby improving vascular function and delaying both microvascular and macrovascular disease progression. However, the clinical translation of natural products still faces multiple challenges and requires comprehensive mechanistic studies and rigorous validation to fully realize their therapeutic potential.

Indexed as

diabetes mellitusinflammationmulti-target therapynatural productsoxidative stressvascular complications

Identifiers

PMID40864768
PMCPMC12384710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.